分子核医学的发展和应用前景

分子核医学是分子影像学的重要组成部分,主要包括PET和SPECT技术。目前,CT、MRI、超声、光学成像等影像技术与分子核医学影像技术的融合,以及多模式放射性药物探针的研究及应用成为核医学的主要发展方向。分子核医学在疾病的生物治疗疗效评估研究,基因治疗及其监测,干细胞生长、繁殖、迁移监测,以及新药的开发和筛选等生命科学研究方面将有越来越广泛的应用。     

心血管核医学分子影像研究进展

心血管分子影像研究是一项崭新且具有巨大临床应用前景的课题,核医学影像是目前分子影像学的主流技术之一,具有无创伤性、灵敏度高、合乎生理条件、可定量等优点,代表了分子影像学发展的前沿.近年来,核医学在心血管分子影像的研究中取得了突出成绩,为心血管疾病的病理生理过程研究以及基因治疗的监测开辟了广阔的空间.     

《中华核医学与分子影像杂志》稿约

《中华核医学与分子影像杂志》为中华医学会主办的核医学与分子影像专业学术期刊,以广大核医学及分子影像工作者为主要读者对象,报道该领域领先的科研成果和临床诊疗经验,以及对核医学与分子影像临床有指导作用、且与核医学与分子影像临床密切结合的基础理论研究。本刊的办刊宗旨是：贯彻党和国家的卫生工作方针政策,贯彻理论与实践、普及与提高相结合的方针,反映我国核医学与分子影像临床科研工作的重大进展,促进国内外核医学与分子影像学术交流。本刊欢迎论著、短篇论著、病例报告、讲座、综述、国内外学术动态、会议（座谈）纪要、读片集萃、技术交流、新技术研究或应用等栏目的稿件。述评、专论等主要为约稿。     

《中华核医学与分子影像杂志》稿约

《中华核医学与分子影像杂志》为中华医学会主办的核医学与分子影像专业学术期刊,以广大核医学及分子影像工作者为主要读者对象,报道该领域领先的科研成果和临床诊疗经验,以及对核医学与分子影像临床有指导作用、且与核医学与分子影像临床密切结合的基础理论研究。本刊的办刊宗旨是：贯彻党和国家的卫生工作方针政策,贯彻理论与实践、普及与提高相结合的方针,反映我国核医学与分子影像临床科研工作的重大进展,促进国内外核医学与分子影像学术交流。一、本刊欢迎论著、短篇论著、病例报告、讲座、综述、国内外学术动态、会议（座谈）纪要、读片集萃、技术交流、新技术研究或应用、质量控制、经验介绍及专题研究等栏目的稿件。述评、专论等稿件主要为约稿。     

《中华核医学与分子影像杂志》稿约

《中华核医学与分子影像杂志》为中华医学会主办的核医学与分子影像专业学术期刊,以广大核医学及分子影像工作者为主要读者对象,报道该领域领先的科研成果和临床诊疗经验,以及对核医学与分子影像临床有指导作用、且与核医学与分子影像临床密切结合的基础理论研究。本刊的办刊宗旨是:贯彻党和国家的卫生工作方针政策,贯彻理论与实践、普及与提高相结合的方针,反映我国核医学与分子影像临床科研工作的重大进展,促进国内外核医学与分子影像学术交流。本刊欢迎论著、短篇论著、病例报告、讲座、综述、国内外学术动态、会议(座谈)纪要、读片集萃、技术交流、新技术研究或应用等栏目的稿件。述评、专论等主要为约稿。     

《中华核医学与分子影像杂志》稿约

《中华核医学与分子影像杂志》为中华医学会主办的核医学与分子影像专业学术期刊,以广大核医学及分子影像工作者为主要读者对象,报道该领域领先的科研成果和临床诊疗经验,以及对核医学与分子影像临床有指导作用、且与核医学与分子影像临床密切结合的基础理论研究。本刊的办刊宗旨是：贯彻党和国家的卫生工作方针政策,贯彻理论与实践、普及与提高相结合的方针,反映我国核医学与分子影像临床科研工作的重大进展,促进国内外核医学与分子影像学术交流。本刊欢迎论著、短篇论著、病例报告、讲座、综述、国内外学术动态、会议（座谈）纪要、读片集萃、技术交流、新技术研究或应用等栏目的稿件。述评、专论等主要为约稿。     

《中华核医学与分子影像杂志》稿约

《中华核医学与分子影像杂志》为中华医学会主办的核医学与分子影像专业学术期刊,以广大核医学及分子影像工作者为主要读者对象,报道该领域领先的科研成果和临床诊疗经验,以及对核医学与分子影像临床有指导作用、且与核医学与分子影像临床密切结合的基础理论研究。本刊的办刊宗旨是:贯彻党和国家的卫生工作方针政策,贯彻理论与实践、普及与提高相结合的方针,反映我国核医学与分子影像临床科研工作的重大进展,促进国内外核医学与分子影像学术交流。本刊欢迎论著、短篇论著、病例报告、讲座、综述、国内外学术动态、会议(座谈)纪要、读片集萃、技术交流、新技术研究或应用等栏目的稿件。述评、专论等主要为约稿。     

多模式分子影像研讨会暨《中华核医学杂志》更名为《中华核医学与分子影像杂志》发布会在福州举行

多模式分子影像技术在临床上发挥着越来越积极的作用。为推动核医学与分子影像的发展,《中华核医学与分子影像杂志》、中华医学会核医学分会和国药励展于2011年11月1日在福州联合举办了“多模式分子影像研讨会暨《中华核医学杂志》更名为《中华核医学与分子影像杂志》发布会”。出席本次会议的代表共有50余名,除核医学专家外,还有来自从事分子影像设备研究、图像处理软件开发、光学成像和超声成像分子探针研究、放射学与超声学的专家。     

光学分子影像技术在转基因动物模型中的应用研究

光学分子影像技术是一门快速发展的生物医学影像技术,能非侵袭性、定量及实时动态监测活体动物体内的生物学过程,操作简单、实时、灵敏度高、价格低等优点使其越来越多地应用到医学和生命科学等领域.通过建立携带光学分子影像报告基因的转基因动物模型加快了该领域的发展,也拓宽了光学分子影像技术的应用范围.光学分子影像技术联合转基因动物模型在监测肿瘤发生、发展及转移、监测细胞增殖、周期和凋亡、监测机体炎性反应和血管生成以及药物研发等领域均有良好的发展前景.     

《中华核医学与分子影像杂志》稿约

《中华核医学与分子影像杂志》为中华医学会主办的核医学与分子影像专业学术期刊,以广大核医学及分子影像工作者为主要读者对象,报道该领域领先的科研成果和临床诊疗经验,以及对核医学与分子影像临床有指导作用、且与核医学与分子影像临床密切结合的基础理论研究。本刊的办刊宗旨是：贯彻党和国家的卫生工作方针政策,贯彻理论与实践、普及与提高相结合的方针,反映我国核医学与分子影像临床科研工作的重大进展,促进国内外核医学与分子影像学术交流。     

分子成像技术的研究进展

分子成像是新时代的医学成像,它可以无创性监测活体内的细胞和分子水平的生物学过程,其中包括核医学分子显像、磁共振分子成像、超声分子成像、光学分子成像和X射线分子成像等.目前,由于多学科融合的发展,多模式融合成像技术已成功用于临床,如PET-CT和PET-MRI.随着分子探针的发展和多模式融合成像技术的成熟,越来越多的分子...     

Molecular imaging: an overview and clinical applications

Molecular imaging is a new medical discipline that integrates cell biology, molecular biology and diagnostic imaging. Clinical applications of molecular imaging include the use of nuclear medicine, magnetic resonance imaging (MRI) and ultrasound (US). The nuclear medicine applications utilize devices such as single photon emission computerized tomography (SPECT) and positron emission tomography (PET). Molecular imaging has two basic applications. The first is diagnostic imaging, which is used to determine the location and extent of targeted molecules specific to the disease being assessed. The second is therapy, which is used to treat specific disease-targeted molecules. The basic principle of the diagnostic imaging application is derived from the ability of cell and molecular biologists to identify specific receptor sites associated with target molecules that characterize the disease process to be studied. The biology teams then develop molecular imaging agents, which will bind specifically to the target molecules of interest. The principle for using molecular targeting therapy is based on an extension of the diagnostic imaging principle. Basically, it is assumed that if the molecular probe does target the specific disease molecules of interest, the same molecular agent can be loaded with an agent that will deliver therapy to the targeted cells. Patients and physicians have the clinical expectation that molecular imaging, when used for diagnostic purposes, will significantly improve the time-liness as well as the accuracy of detecting the presence and extent of disease. When applied to therapy, the expectation is that FDA-approved agents will have been shown in clinical trials to provide a significant improvement in clinical outcomes over traditional therapy methods. The eventual clinical owners of molecular imaging may be a specialty group that is a hybrid by conventional measures. For example, the clinical owner should have fundamental knowledge in basic cellular and molecular biology but must also be certified as well as competent in the specific diagnostic imaging specialty applied (i.e. nuclear, MR or ultrasound). If the owner is also to be involved with therapy, experience and appropriate certification will also be required. Another issue relates specifically to the therapy applications in oncology. It is conceivable that traditional chemotherapy and radiotherapy may be replaced in part with molecular imaging therapy that utilizes target-specific agents to treat cancer on a non-toxic, outpatient basis. The issue to be addressed by the radiology administrator is whether this new discipline will be performed in the radiology department or oncology and radiotherapy departments. Clearly, radiology and its associated diagnostic imaging subspecialties are the most logical owner of molecular imaging. However, to make this ownership a reality will require major shifts in training requirements, as well as exertion of political influence from the radiology administrators against other specialties that have much to lose in terms of patient populations and revenue to their practice.     

Nuclear medicine at a crossroads

The growth of molecular imaging heightens the promise of clinical nuclear medicine as a tool for individualization of patient care and for improvement of health-care outcomes. Together with greater use of integrated structure-function imaging, clinical nuclear medicine reaches beyond traditional specialty borders into diagnostic radiology and oncology. Yet, there are concerns about the future of nuclear medicine, including progressively declining reimbursement, the competitive advantages of diagnostic radiology, limited translation of research accomplishments to clinical diagnostic imaging and patient care, and an insufficient pool of incoming highly qualified nuclear medicine clinicians. Thus, nuclear medicine views itself as being at a critical crossroads. What will be important is for nuclear medicine to be positioned as the quintessential molecular imaging modality more centrally within medical imaging and for the integration of nuclear medicine with primary care specialties to be driven more by patient needs than by specialty needs. In this way, the full potential of nuclear medicine as an effective and efficient tool for improving patient outcomes can be realized.     

PET: a revolution in medical imaging

FDG-PET has had remarkable influence on the assessment of physiologic and pathologic states. The authors predict that FDG-PET imaging could soon become the most common procedure used by nuclear medicine laboratories and could remain so for an extended period of time. The power of molecular imaging lies in the vast potential for using biochemical and pharmacologic probes to extend applications arising from an understanding of cell biology to a large number of well-characterized pathologic states. Molecular imaging based upon tracer kinetics with positron-emitting radiopharmaceuticals could become the main source of information for the management of cancer patients. In that case, nuclear medicine procedures might become the most common imaging studies performed in the practice of medicine. This speculation is not farfetched when one realizes the enormous change that a single biologically important compound, FDG, has brought to the medical arena. The major challenge today is to attract the highly qualified individuals and to secure the resources needed to harness the opportunities in the specialty of molecular imaging.     

Molecular imaging and gene therapy.

Molecular imaging is an emerging field of study that deals with imaging of disease on a cellular or genetic level rather than on a gross level. Recent advances in this field show promise, particularly in the imaging of gene expression. This article reviews the use of nuclear medicine, magnetic resonance, and optic imaging to visualize gene expression. A review is presented of current in vitro assays for protein and gene expression and the translation of these methods into the radiologic sciences. The merging fields of molecular biology, molecular medicine, and imaging modalities may provide the means to screen active drugs in vivo, image molecular processes, and diagnose disease at a presymptomatic stage.     

Molecular theranostics: a primer for the imaging professional

OBJECTIVE: A theranostic system integrates some form of diagnostic testing to determine the presence of a molecular target for which a specific drug is intended. Molecular imaging serves this diagnostic function and provides powerful means for noninvasively detecting disease. We briefly review the paradigms rooted in nuclear medicine and highlight recent advances in this field. We also explore how nanometer-sized complexes, called nanomedicines, present an excellent theranostic platform applicable to both drug discovery and clinical use. CONCLUSION: For imagers, molecular theranostics represents a powerful emerging platform that intimately couples targeted therapeatic entities with noninvasive imaging that yields information on the presence of defined molecular targets before, during, and after cognate therapy.     

Molecular body imaging: MR imaging, CT, and US. part I. principles

Molecular imaging, generally defined as noninvasive imaging of cellular and subcellular events, has gained tremendous depth and breadth as a research and clinical discipline in recent years. The coalescence of major advances in engineering, molecular biology, chemistry, immunology, and genetics has fueled multi- and interdisciplinary innovations with the goal of driving clinical noninvasive imaging strategies that will ultimately allow disease identification, risk stratification, and monitoring of therapy effects with unparalleled sensitivity and specificity. Techniques that allow imaging of molecular and cellular events facilitate and go hand in hand with the development of molecular therapies, offering promise for successfully combining imaging with therapy. While traditionally nuclear medicine imaging techniques, in particular positron emission tomography (PET), PET combined with computed tomography (CT), and single photon emission computed tomography, have been the molecular imaging methods most familiar to clinicians, great advances have recently been made in developing imaging techniques that utilize magnetic resonance (MR), optical, CT, and ultrasonographic (US) imaging. In the first part of this review series, we present an overview of the principles of MR imaging-, CT-, and US-based molecular imaging strategies.